NPS+ (EU5) [CLL]

Wednesday, November 29, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Why are some EU5 CLL brands standing out more than others?

LONDON, Nov. 28, 2017 /PRNewswire/ -- There are various options available to EU5 oncologists and haematologists to treat

chronic lymphocytic leukaemia (CLL). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? Download the full report: CLL (EU5) gives a unique insight into the overall brand health of 6 leading treatments for CLL currently being used in the EU5 markets. 150 oncologists and haematologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out. Top Takeaways Six brands surveyed, five positive NPS. In Europe, 5 of the 6 brands surveyed obtained positive brand health scores, but 1 didn't. Is it your brand languishing at the bottom of the table, and what could you do about it? High loyalty for one brand, not so much for the others. Loyalty scores of less than 3 indicate low loyalty, and only one brand manages to score above this magic number. Is clinical differentiation really that low, or does the leading brand really offer something that the others can’t? Satisfaction high, but this is shared across multiple brands. Unlike US physicians, EU5 physicians are very satisfied with current treatment options. The only issue? This satisfaction is shared across multiple brands. Is there a dominant brand message? Find out which messages are resonating with physicians, and take your brand’s positioning strategy to another level. In their own words. What do doctors say each brand means to them? For example, which brand is described as “the immediate future, a paradigm shift in treatment” and which brand is dubbed as expensiveť? Insight into 6 CLL Treatments Arzerra (ofatumumab; Novartis) Gazyvaro (obinutuzumab; Roche) Imbruvica (ibrutinib; AbbVie/Janssen Cilag) MabThera (rituximab; Roche) Venclyxto (venetoclax; AbbVie) Zydelig (idelalisib; Gilead) Explore Important Brand Loyalty Issues NPS+ CLL (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for CLL to patients. You’ll discover: Exactly how satisfied the European market is. How loyal doctors are to your brand. How many other brands your Promoters recommend. Which other brands your Promoters and Detractors recommend. How much market share your brand has among Promoters and Detractors. How much market share you stand to gain by converting Detractors into Promoters. Which messages Promoters, Passives and Detractors associate with your brand. Your brand DNA: what doctors really think of your brandâ€"in their own words. A Report Based on Expert Knowledge We surveyed 150 oncologists and haematologists chosen from the largest community of validated physicians in the world. We conducted the survey between September 1-14, 2017. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow. How does NPS work? NPS measures overall brand satisfaction and loyalty by asking one simple question: "How likely are you to recommend this brand to a colleague?" Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)â€"are used to classify respondents into 3 categories: Detractors are those who answer 0 - 6. Passives are those who answer 7 - 8. Promoters are those who answer 9 - 10. How is NPS calculated? The percentage of detractors - the percentage of promoters = NPS. For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5. NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty. Each NPS+ report examines doctors™ relationships with the brands used to treat a major disease areaâ€"measuring brand loyalty and showing you how it affects your market share. NPS+ also examines brand DNA, revealing in doctors’ own words what brands mean to them. Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.Download the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

View original content:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store